Join
Live feed
·
PRReleasevia Quantisnow
Dianthus Therapeutics Inc. logo

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

ByQuantisnow·Wall Street's wire, on your screen.
DNTH· Dianthus Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DNTH (Dianthus Therapeutics Inc.) and more on Quantisnow.